Oncology asset valuation for fundraising support

Challenge: A clinical stage biotech company developing novel oncology treatments was planning a private funding round to progress the clinical development of its lead product. The biotech requested...
Learn More

Valuation of pipeline for fundraising activities

Challenge: An oncology biotech company with a proprietary therapeutics development platform technology was in the process of fundraising activities. The company's pipeline included three main...
Learn More

Valuation and deal making for oncology antibody

Challenge: A biotechnology company developing novel multi-specific antibody therapeutics to treat a range of cancers asked Alacrita to develop valuations for its four leading assets, as well as...
Learn More

Scouting in-licensing targets in inflammation and fibrosis

Challenge: A pharmaceutical company with marketed therapeutics in several respiratory disorders wanted to supplement its internal pipeline with external innovation. The company had already searched...
Learn More

Providing due diligence for a company developing R&D tools using pluripotent stem cells

Challenge: A UK-based VC wished to invest in a biotech spin-out focussed on the development of R&D tools using induced pluripotent stem cells (iPSCs) as organoids to mimic human tissues. These...
Learn More

Investor due diligence on preclinical stage vaccine platform technology

Challenge: Following a pre-due diligence exercise, an investment firm asked Alacrita to conduct a deeper due diligence on a biotech company's vaccine platform technology targeted towards infectious...
Learn More

Investor due diligence on clinical stage oncology therapeutic company

Challenge: A VC investor asked Alacrita to conduct due diligence on a clinical stage oncology therapeutic company developing a targeted inhibitor that works via the notch pathway. Priority...
Learn More

Due diligence for VC firm

Challenge: A government owned investment firm was considering an investment in a small biopharma company developing a therapeutic monoclonal antibody against a novel immuno-oncology target.  Alacrita...
Learn More

Providing reality checks on commercial opportunities

Challenge:  A transatlantic life science venture capital fund was contemplating investing in advanced plasma product opportunities being developed by a biopharmaceutical company, and needed a reality...
Learn More

Providing diagnostics due diligence

Challenge: A major European venture capital investor needed to analyze the business plan of a novel point-of-care diagnostics company.
Learn More

Preclinical due diligence of novel live biotherapeutic

Challenge: An early-stage venture fund asked Alacrita to review the opportunity for reinvestment in a biotech developing a novel live biotherapeutic for the treatment of inflammatory bowel disorders...
Learn More

Due diligence for a new imaging technology

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.
Learn More
Content not found